CAD 0.87
(-4.4%)
Year | Inventory | Inventory Growth |
---|---|---|
2024 | - USD | -100.0% |
2023 | 5.67 Million USD | 0.0% |
2022 | - USD | -100.0% |
2021 | 516.23 Thousand USD | 159.37% |
2020 | 199.03 Thousand CAD | 2358.06% |
2019 | 8097.08 CAD | 809701944809.91% |
2018 | - CAD | -100.0% |
2017 | 0.84 CAD | 99.14% |
2016 | 0.42 CAD | 42412677.04% |
2015 | - CAD | -100.0% |
2014 | 0.49 CAD | 149.59% |
2013 | 0.20 CAD | 109.86% |
2012 | 0.09 CAD | 9320858.8% |
2011 | - CAD | 100.0% |
2010 | -0.17 CAD | -224.92% |
2009 | -0.05 CAD | 0.0% |
2008 | - CAD | 0.0% |
2007 | - CAD | 0.0% |
2006 | - CAD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | 5.45 Million USD | 15.33% |
2024 Q1 | 4.73 Million USD | -16.52% |
2024 Q3 | -1.71 Million USD | -131.35% |
2024 Q4 | - USD | 100.0% |
2023 Q4 | 5.67 Million USD | 330.87% |
2023 Q3 | 1.31 Million USD | 206.94% |
2023 Q2 | 428.81 Thousand USD | 0.0% |
2023 Q1 | - USD | 0.0% |
2023 FY | 5.67 Million USD | 0.0% |
2022 Q3 | - USD | 100.0% |
2022 Q2 | -83.4 Thousand USD | 14.41% |
2022 Q1 | -97.44 Thousand USD | 0.0% |
2022 FY | - USD | -100.0% |
2022 Q4 | - USD | 0.0% |
2021 Q2 | -56.69 Thousand CAD | 16.06% |
2021 FY | 516.23 Thousand USD | 159.37% |
2021 Q1 | -67.54 Thousand CAD | 0.0% |
2021 Q4 | - USD | 100.0% |
2021 Q3 | -160.81 Thousand CAD | -183.64% |
2020 Q2 | - CAD | 0.0% |
2020 Q4 | - CAD | 0.0% |
2020 FY | 199.03 Thousand CAD | 2358.06% |
2020 Q1 | - CAD | 0.0% |
2020 Q3 | - CAD | 0.0% |
2019 Q3 | - CAD | 0.0% |
2019 Q1 | - CAD | 0.0% |
2019 FY | 8097.08 CAD | 809701944809.91% |
2019 Q4 | - CAD | 0.0% |
2019 Q2 | - CAD | 0.0% |
2018 Q3 | - CAD | 0.0% |
2018 FY | - CAD | -100.0% |
2018 Q4 | - CAD | 0.0% |
2018 Q2 | - CAD | 0.0% |
2018 Q1 | - CAD | 0.0% |
2017 Q1 | - CAD | 0.0% |
2017 Q4 | - CAD | 0.0% |
2017 FY | 0.84 CAD | 99.14% |
2017 Q3 | - CAD | 0.0% |
2017 Q2 | - CAD | 0.0% |
2016 Q4 | - CAD | 0.0% |
2016 Q1 | - CAD | 0.0% |
2016 Q3 | - CAD | 0.0% |
2016 Q2 | - CAD | 0.0% |
2016 FY | 0.42 CAD | 42412677.04% |
2015 Q2 | - CAD | -100.0% |
2015 FY | - CAD | -100.0% |
2015 Q3 | - CAD | 0.0% |
2015 Q4 | - CAD | 0.0% |
2015 Q1 | 1.85 Million CAD | 0.0% |
2014 FY | 0.49 CAD | 149.59% |
2014 Q4 | - CAD | 0.0% |
2014 Q3 | - CAD | 0.0% |
2014 Q2 | - CAD | 0.0% |
2014 Q1 | - CAD | 0.0% |
2013 Q3 | - CAD | 0.0% |
2013 Q2 | - CAD | 0.0% |
2013 Q1 | - CAD | 0.0% |
2013 FY | 0.20 CAD | 109.86% |
2013 Q4 | - CAD | 0.0% |
2012 Q4 | - CAD | 0.0% |
2012 Q3 | - CAD | 0.0% |
2012 Q2 | - CAD | 0.0% |
2012 Q1 | - CAD | 0.0% |
2012 FY | 0.09 CAD | 9320858.8% |
2011 Q1 | - CAD | 0.0% |
2011 Q2 | - CAD | 0.0% |
2011 Q3 | - CAD | 0.0% |
2011 Q4 | - CAD | 0.0% |
2011 FY | - CAD | 100.0% |
2010 Q1 | - CAD | 0.0% |
2010 Q3 | - CAD | 0.0% |
2010 Q2 | - CAD | 0.0% |
2010 FY | -0.17 CAD | -224.92% |
2010 Q4 | - CAD | 0.0% |
2009 Q3 | - CAD | 0.0% |
2009 Q4 | - CAD | 0.0% |
2009 Q2 | - CAD | 0.0% |
2009 Q1 | - CAD | 0.0% |
2009 FY | -0.05 CAD | 0.0% |
2008 FY | - CAD | 0.0% |
2008 Q4 | - CAD | 0.0% |
2008 Q3 | - CAD | 0.0% |
2008 Q2 | - CAD | 0.0% |
2008 Q1 | - CAD | 0.0% |
2007 Q4 | - CAD | 0.0% |
2007 Q2 | - CAD | 0.0% |
2007 Q3 | - CAD | 0.0% |
2007 Q1 | - CAD | 0.0% |
2007 FY | - CAD | 0.0% |
2006 FY | - CAD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
Appili Therapeutics Inc. | - CAD | NaN% |
Eupraxia Pharmaceuticals Inc. | 1.00 CAD | 100.0% |
Helix BioPharma Corp. | - CAD | NaN% |
Microbix Biosystems Inc. | 5.75 Million CAD | 100.0% |
Medicenna Therapeutics Corp. | - CAD | NaN% |
Satellos Bioscience Inc. | -583 Thousand CAD | 100.0% |
Oncolytics Biotech Inc. | - CAD | NaN% |
Sernova Corp. | - CAD | NaN% |